Vimentin: Central hub in EMT induction?

Small GTPases

Volumn 2, Issue 1, 2011, Pages

  Ivaska, Johanna ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Akt; Axl; EMT; Migration; Polarity; Ras; Vimentin

Indexed keywords

AXL PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 79960315948     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18:813-22.
2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22.
3. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2010; In press.
4. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010; 38:114-27.
5. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100:35-83.
6. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010; 70:1544-54.
7. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010; 29:5254-64.
8. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial- to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 2010; 107:1124-9.
9. Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, et al. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 1999; 112:4615-25.
10. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios. Epithelialmesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008; 68:989-97.
11. Eckes B, Dogic D, Colucci-Guyon E, Wang N, Maniotis A, Ingber D, et al. Impaired mechanical stability, migration and contractile capacity in vimentindeficient fibroblasts. J Cell Sci 1998; 111:1897-907.
12. Eckes B, Colucci-Guyon E, Smola H, Nodder S, Babinet C, Krieg T, et al. Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 2000; 113:2455-62.
13. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility and adhesion during the epithelial to mesenchymal transition. FASEB J 2010; 24:1838-51.
14. Phua DC, Humbert PO, Hunziker W. Vimentin regulates scribble activity by protecting it from proteasomal degradation. Mol Biol Cell 2009; 20:2841-55.
15. Burgstaller G, Gregor M, Winter L, Wiche G. Keeping the vimentin network under control: cellmatrix adhesion-associated plectin 1f affects cell shape and polarity of fibroblasts. Mol Biol Cell 2010; 21:3362-75.
16. Kreis S, Schonfeld HJ, Melchior C, Steiner B, Kieffer N. The intermediate filament protein vimentin binds specifically to a recombinant integrin alpha2/beta1 cytoplasmic tail complex and co-localizes with native alpha2/beta1 in endothelial cell focal adhesions. Exp Cell Res 2005; 305:110-21.
17. Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 2011; 30:457-70.